Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
mediaposted on 15.04.2021, 13:27 by Adis journals on behalf of, Jai Perumal, Roumen Balabanov, Ray Su, Roger Chang, Laura Balcer, Steven Galetta, Denise I. Campagnolo, Robin Avila, Lily Lee, Danette Rutledge, Robert J. Fox
Article full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.